By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Despite strong Asia growth and wealth inflows, panelists express concerns about persistent mental health-related claims in Canada, regulatory risks in Hong Kong, and the sustainability of Manulife's pricing power.
Risk: The potential loss of pricing power in Canada due to mental health-driven claims and the risk of regulatory tightening in Hong Kong's wealth management sector.
Opportunity: The 136% LICAT ratio providing optionality for capital returns and further reinsurance or buybacks.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Manulife delivered strong second-quarter growth:APE sales rose 21%, core earnings increased 12%, and core EPS climbed 16%, with core ROE reaching 16.3%. Asia and wealth management were key contributors, including record Asian earnings and CAD 4 billion in global wealth-management net inflows.
Canada's sales momentum was offset by claims pressure:Canadian APE sales grew 23%, but core earnings fell 10% because of unfavorable disability and group-insurance claims experience. Management expects insurance experience to trend toward neutral by the end of 2026 and retains the ability to reprice group-insurance policies.
A new long-term-care reinsurance deal reduced risk while capital remained strong:The Munich Re agreement transfers biometric risk on CAD 3.2 billion of reserves, bringing total long-term-care morbidity-risk reduction to 24%. Manulife ended the quarter with a 136% LICAT ratio and returned CAD 1.4 billion to shareholders through dividends and buybacks.
Manulife Financial (NYSE:MFC) reported second-quarter 2026 results marked by double-digit growth in insurance sales, higher core earnings and continued capital returns, while also announcing a third long-term care reinsurance transaction in three years.
<pre><code> President and Chief Executive Officer Phil Witherington said annualized premium equivalent, or APE, sales increased 21% from a year earlier, supported by double-digit growth in each insurance segment. New business contractual service margin rose 16%, while the company's total CSM balance increased 20%. → Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling Core earnings rose 12% year over year and core earnings per share increased 16%, helped by ongoing share repurchases. Manulife reported core return on equity of 16.3%, up 130 basis points from the prior-year quarter. Net income totaled CAD 2.1 billion, exceeding core earnings as higher-than-expected public equity returns more than offset lower-than-expected returns on alternative long-duration assets. ## Asia and wealth management drive growth Asia remained a major source of growth. Core earnings in the region increased 21% to a record level, while APE sales rose 21%, led by double-digit gains in Hong Kong, Singapore and Japan. Hong Kong APE sales climbed 37%, reflecting higher savings-product sales across distribution channels, according to Chief Financial Officer Colin Simpson. → 4 Oil and Gas ETF Plays as Prices Stay Sky-High Manulife Asia President and CEO Steve Finch said the company's Hong Kong business remained diversified, with its domestic franchise accounting for about 75% of year-to-date sales. Mainland Chinese visitor, or MCV, business represented about 25% of sales, though that mix can vary by period. Analysts asked about potential effects from Chinese regulatory and tax enforcement developments involving offshore insurance policies and investments. Finch said it was too early to assess implications, but he did not expect mainland Chinese visitor sales to go to zero and said any near-term impact would be manageable. He added that Manulife expects the longer-term trend of mainland Chinese customers accessing Hong Kong for products and services to continue. → No Hangover: Revisiting Microsoft One Week After Earnings Finch said Hong Kong's second-quarter sales growth was driven principally by customer offerings and campaigns rather than accelerated purchasing ahead of regulatory changes. Growth in agency and bancassurance more than offset lower MCV sales year over year, he said. In Global Wealth and Asset Management, Manulife recorded CAD 4 billion of net inflows, driven by institutional business and continued contributions from CQS and Comvest. The result was partially offset by outflows in North American retirement and retail channels. Global WAM core earnings rose 9%, while its core EBITDA margin expanded 110 basis points to 31.2%. Simpson said retirement outflows reflected planned sponsor redemptions and higher member withdrawals associated with market-driven account appreciation. Retail outflows were primarily tied to active mutual-fund redemptions through third-party intermediaries in Canada, although trends improved sequentially. ## Canada claims pressure offsets sales momentum Canadian APE sales increased 23%, led by higher large-case group insurance sales and continued strength in participating life insurance. New business CSM in Canada rose 29%, though new business value was largely flat due to lower margins and product-mix changes in group benefits. Canadian core earnings declined 10% from the prior year, primarily because of unfavorable claims and expense experience in group insurance, as well as normal claims variability in individual insurance. Manulife said overall insurance experience improved modestly from the first quarter and expects it to trend toward neutral by the end of 2026. Patrick Graham, President and CEO of Manulife Canada, said unfavorable morbidity experience has been driven largely by disability claims. About one-third of new disability claims are related to mental health, which he said can extend claim duration. The company is investing in earlier intervention, treatment access and specialized case-management teams intended to improve customer outcomes and support return-to-work efforts. Graham also said Manulife's group insurance business can be repriced annually. Witherington said the company has both the ability and intent to reprice if adverse experience persists. In the U.S., APE sales rose 12%, supported by product enhancements and distribution expansion. Core earnings improved from the prior year as claims experience improved in life and long-term care and the expected credit loss provision charge declined. U.S. life claims remained unfavorable during the quarter but improved meaningfully from the prior year, while long-term care experience was favorable in both earnings and CSM. ## Long-term care transaction reduces morbidity risk Manulife announced a reinsurance agreement with Munich Re covering an older-vintage standalone long-term care block. The transaction transfers biometric risk on CAD 3.2 billion of reserves through an 80% quota share arrangement, while Manulife retains the assets backing the business and their associated investment-management economics. Witherington said the agreement represents a full transfer of biometric risk and has pricing similar to prior long-term care transactions, including a modest negative cede. The transaction is expected to be largely capital neutral because lower morbidity-risk capital requirements are offset by the release of the related risk adjustment and ceding commission. No assets are being transferred, meaning there is no capital benefit from asset disposal. The company expects foregone core earnings of about CAD 30 million in the first year, declining as the block runs off. Including previous transactions, Manulife said it will have reduced long-term care morbidity risk by 24%. Chief Actuary Stephanie Fadous said the retained long-term care block is somewhat younger and is expected to remain relatively stable before beginning to decline over the next five to 10 years. She said IFRS and statutory capital generation should begin around the same time. The newly reinsured block is more mature and has richer benefits, suggesting capital generation on the retained assets should occur sooner for that block. Management said it intends to place greater emphasis on organic management of the remaining long-term care portfolio while retaining flexibility to pursue future transactions. Witherington said Manulife's long-term care customer-care program has generated a current run rate of more than 6% in claims savings through measures including enhanced claims management and efforts to reduce fraud, waste and abuse. ## Capital position and shareholder returns Manulife ended the quarter with a LICAT ratio of 136%, representing CAD 26 billion above its supervisory target ratio. Its financial leverage ratio was 22.2%, below its medium-term target of 25%. Adjusted book value per share increased 15% year over year to CAD 41.12. Over the past 12 months, the company returned CAD 5.3 billion of capital to shareholders, including CAD 1.4 billion during the second quarter through dividends and share buybacks. Management said its current 2.5% share-repurchase program is consistent with reaching its target of core return on equity above 18%, without requiring an outsized buyback program. Simpson said Manulife expects its annual corporate result to fall within a CAD 300 million to CAD 400 million loss range, likely toward the higher end, reflecting softer property-and-casualty retrocession conditions and higher spending on central projects, particularly artificial intelligence. ## About Manulife Financial (NYSE:MFC) Manulife Financial Corporation is a multinational insurance and financial services company headquartered in Toronto, Ontario. Founded in the late 19th century as The Manufacturers Life Insurance Company, Manulife provides a broad range of financial products and services to individual and institutional clients. Its core businesses include life and health insurance, retirement and pension solutions, wealth and asset management, and group benefits. In wealth and asset management, Manulife operates through Manulife Investment Management and offers mutual funds, segregated funds, institutional asset management, and retirement plan solutions. *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].* The article "Manulife Financial Q2 Earnings Call Highlights" was originally published by MarketBeat. **View MarketBeat's top stocks for August 2026****.** </code></pre>Four leading AI models discuss this article
"Asia-driven growth and LTC de-risking outweigh near-term Canadian claims pressure, supporting further re-rating from 9.5x forward P/E."
MFC delivered robust Q2 with 21% APE sales growth, 16% core EPS rise, record Asia earnings, CAD 4B wealth inflows, and a 136% LICAT ratio supporting CAD 1.4B in buybacks/dividends. Asia (esp. Hong Kong up 37%) and wealth management are clear engines, while the Munich Re LTC reinsurance trims morbidity risk by another 8% to 24% total. Core ROE at 16.3% is trending toward the >18% target. However, persistent Canadian disability/group claims (mental health driven) dragged earnings 10%, with normalization not expected until end-2026; repricing helps but volumes could suffer. Hong Kong MCV exposure (25% of sales) carries regulatory/tax risk the article downplays. Valuation at ~9.5x forward P/E looks attractive on 12-15% EPS CAGR.
If Canadian morbidity experience stays adverse beyond 2026 or Hong Kong/China regulatory tightening materially cuts MCV sales, the earnings drag could offset Asia/wealth tailwinds and stall ROE progress, making the current multiple expansion premature.
"Manulife's reliance on repricing to offset rising disability claims suggests that their Canadian margin expansion is at risk of being structurally capped by social-health trends."
Manulife’s 16% core EPS growth and 16.3% ROE are impressive, but the narrative hinges on aggressive capital management and risk offloading rather than pure organic margin expansion. While the 21% APE growth in Asia is a clear tailwind, the 10% core earnings decline in Canada due to mental health-related disability claims is a structural red flag. Management’s reliance on annual group repricing is a reactive, not proactive, strategy. Furthermore, the CAD 30 million annual earnings drag from the Munich Re deal highlights that 'de-risking' comes at a permanent cost to the bottom line. At a 136% LICAT ratio, they are over-capitalized, but future growth must come from underwriting discipline, not just reinsurance accounting.
The 'claims pressure' in Canada may be a transitory spike rather than a structural shift, and the successful offloading of legacy long-term care risk significantly improves the quality of earnings by removing tail-risk volatility.
"MFC is trading on strong sales and capital returns, but Canadian profitability deterioration and unresolved claims inflation create downside risk that repricing and Asia growth must overcome by late 2026."
MFC's headline numbers mask a structural profitability problem. Yes, APE sales +21% and core EPS +16% look strong, but Canadian core earnings fell 10% despite 23% sales growth—a massive margin compression signal. The disability/mental-health claims crisis isn't a one-quarter blip; management admits it won't normalize until end-2026, and repricing group insurance annually means competitive pressure and potential customer loss. The Munich Re reinsurance deal costs CAD 30M in year-one earnings to shed risk—sensible risk management, but it's earnings drag. Asia's 37% Hong Kong growth is increasingly China-regulatory-dependent; management's "too early to assess" on MCV regulatory risk is code for "we don't know." The 136% LICAT ratio is comfortable but not exceptional for an insurer.
If repricing succeeds and claims normalize by Q4 2026, Canadian earnings rebound sharply with high operating leverage on the 23% sales base. Asia's diversification (75% domestic Hong Kong) and 21% core earnings growth may justify the regulatory noise as manageable noise.
"The immediate beat largely reflects macro-driven gains and capital-structure tweaks, but the key levers for sustainable outperformance are exposed to Asia/regulatory risk and evolving claims dynamics—not a guaranteed, margin-improving growth trajectory."
Manulife's Q2 print is solid: APE +21%, core EPS +16%, ROE 16.3% driven by Asia and wealth inflows. Yet earnings quality hinges on market-driven gains and ongoing claims dynamics; Canada’s claims pressure remains a risk, and the 24% reduction in long-term-care morbidity risk is a capital efficiency move, not a growth engine. The real swing factors are Asia regulatory/commercial risk (HK/MCV mix) and potential limits to pricing power in group benefits. If markets soften or morbidity trends reaccelerate, ROE and dividend visibility could be pressured, leaving a move higher in the stock multiple contingent on macro stability.
The strongest counter is that Asia results could be fragile amid regulatory shifts, and the long-term-care reinsurance is a one-time capital tweak with uncertain earnings durability; this could cap upside and expose the stock to downside if policy/regulatory risks intensify.
"LICAT strength provides capital flexibility that offsets Canadian claims drag longer than consensus assumes, but HK WM sensitivity to MCV rules remains under-discussed."
Claude correctly flags the Canada margin compression, but underweights the 136% LICAT buffer's optionality: it funds CAD 1.4B capital return while still allowing further reinsurance or buybacks if morbidity drags past 2026. The real overlooked risk is second-order Hong Kong wealth-management inflows drying if Beijing tightens MCV-linked insurance-investment products beyond current rhetoric.
"The Canadian disability claims drag is a temporary repricing lag that the market is over-penalizing relative to the structural growth in Asia."
Claude and Gemini are missing the forest for the trees regarding the Canadian group benefits segment. While the 10% earnings drag from mental health claims is painful, it is fundamentally a repricing lag, not a structural margin collapse. Manulife’s scale allows them to force market-wide rate increases that smaller competitors cannot sustain. The real risk isn't Canadian claims, but the potential for a 'valuation trap' if the market continues to discount MFC as a legacy insurer rather than an Asia-growth play.
"Repricing power is only real if volume holds; MFC's 23% sales growth with 10% earnings decline signals customers are already defecting to cheaper competitors."
Gemini's 'repricing lag, not collapse' argument assumes MFC's pricing power survives intact—but Claude's 23% sales growth with 10% earnings decline suggests volume elasticity is already negative. If competitors match rate hikes, MFC absorbs the volume loss without margin recovery. Gemini's scale-advantage thesis needs evidence: are smaller peers actually unable to reprice, or is MFC losing share because customers are price-sensitive to mental-health-driven claims? That's the real structural risk nobody quantified.
"Repricing alone isn’t a durable margin shield; LICAT-based buybacks may be capped in stress, while rising claims and HK/China regulation could accelerate margin pressure and valuation downside."
Claude flags Canada margin compression, but the deeper flaw is assuming repricing will shield margins. If pricing lags amid rising claims and competitive caution, volume losses may outpace any rate increases. LICAT optionality helps, yet under a stress scenario regulators or rating agencies could curb buybacks, diminishing upside from capital returns. If Asia growth slows or HK/China regulation bite hard, multiple compression could be faster than anticipated.
Despite strong Asia growth and wealth inflows, panelists express concerns about persistent mental health-related claims in Canada, regulatory risks in Hong Kong, and the sustainability of Manulife's pricing power.
The 136% LICAT ratio providing optionality for capital returns and further reinsurance or buybacks.
The potential loss of pricing power in Canada due to mental health-driven claims and the risk of regulatory tightening in Hong Kong's wealth management sector.